Longboard Pharmaceuticals, Inc. announced the initiation of a Phase 1 randomized, double-blind, placebo-controlled, SAD clinical study of LP659. LP659 is an oral, centrally acting, next-generation sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator in development for the potential treatment of rare neuroinflammatory conditions. The primary objective of this Phase 1 randomized, double-blind, placebo-controlled, single-ascending dose clinical study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LP659 in up to 48 healthy adult volunteers.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.79 USD | -1.66% | -5.18% | +245.77% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+245.77% | 822M | |
+6.68% | 113B | |
+10.90% | 106B | |
+0.87% | 22.27B | |
-12.85% | 22.22B | |
-5.71% | 19.43B | |
-37.85% | 17.87B | |
-6.75% | 17.24B | |
+7.39% | 14.29B | |
+34.66% | 12.52B |
- Stock Market
- Equities
- LBPH Stock
- News Longboard Pharmaceuticals, Inc.
- Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers